Transplant News and Research

RSS

Clinical Pharmacokinetics Research Laboratory deploys AB SCIEX mass spectrometry technology

AB SCIEX, a global leader in life science analytical technologies, today announced that the Clinical Pharmacokinetics Research Laboratory at the University of Rhode Island's College of Pharmacy is using AB SCIEX mass spectrometry technology to develop a novel test that would enable clinical researchers to use saliva to monitor immunosuppressant drugs commonly administered to make organ transplants successful.

28 Jul 2010

Researchers establish new criteria for liver transplantation

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 Jul 2010

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Regeneron Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product candidates.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Genzyme Corp.today said it welcomed the Centers for Medicare and Medicaid Services' decision not to include oral medications without IV equivalents in Medicare's End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme's Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014.

28 Jul 2010

FDA approves addition of 10 sites to WorldHeart's Levacor VAD BTT clinical study

World Heart Corporation, a developer of mechanical circulatory systems, announced today that the United States Food and Drug Administration (FDA) has approved the addition of ten sites to the Levacor ventricular assist device (VAD) Bridge-to-Transplant (BTT) clinical study. WorldHeart's pivotal BTT study is now approved to enroll patients at 20 sites in the U.S.

28 Jul 2010

SBHCS deploys MedeAnalytics platform to automate patient access process of health system

MedeAnalytics, a leading provider of healthcare performance management solutions, today announced that the Saint Barnabas Health Care System has selected MedeAnalytics Patient Access Intelligence solution to automate the complete patient access process of the health system.

27 Jul 2010

New partnership brings latest stem cell discoveries from laboratory to patient

A major research company affiliated with the University of Colorado with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

27 Jul 2010

Waters to present MassTrak solutions at American Association of Clinical Chemistry annual meeting

Waters Corporation is showcasing its portfolio of MassTrak solutions at the American Association of Clinical Chemistry annual meeting and Clinical Lab Expo July 25 - 29, 2010 in Anaheim in exhibit booth #4447. Waters portfolio of MassTrak Solutions for the clinical laboratory combines the power of separations science, tandem mass spectrometry, specialized chemistries, software, and support services in ways designed to optimize laboratory processes.

27 Jul 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

UCLA Health System launches hand transplantation program

The UCLA Health System has launched the new UCLA Hand Transplantation Program, the first of its kind on the West Coast and only the fourth such center in the United States. The program will help those who have suffered the traumatic loss of a hand or forearm and allow them to regain function and improve their quality of life. Qualified candidates are now being sought for a clinical study of the procedure.

27 Jul 2010

CPC partners with CU School of Medicine on stem cell research

A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

26 Jul 2010

New guidelines for care of heart transplant recipients from ISHLT

Since the dawn of heart transplantation in the 1960s, medical care of heart transplant recipients has varied from center to center and been guided by the experience of individual clinicians. The International Society for Heart and Lung Transplantation (ISHLT) has made an unprecedented commitment by convening experts in all areas of heart transplantation to develop practice guidelines for the care of heart transplant recipients.

26 Jul 2010

Methodist surgical team completes first phase training to implant new total artificial heart

A 13-member surgical team from the Methodist DeBakey Heart & Vascular Center completed the first phase of training to implant a new total artificial heart designed to completely replace the heart's function while the patient waits for a heart transplant. Methodist will be the first hospital in Texas to offer this total heart replacement.

26 Jul 2010

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx's oncology drug candidate tamibarotene.

23 Jul 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb Company today reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. The company also confirmed guidance for 2010 and minimum guidance for non-GAAP EPS in 2013.

22 Jul 2010

Towards a cure: HIV reservoirs and strategies to control them

Can HIV infection ever be cured? The prospect of efficiently controlling HIV persistence in infected persons was the topic of a high-level, two-day meeting of researchers gathered here on the eve of AIDS 2010, the biennial international conference of HIV researchers, funders, policy-makers and advocates.

22 Jul 2010

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2010.

22 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

First hospital in U.S. to use portable heart/lung machine

The Methodist Hospital is the first in the U.S. to use a portable heart/lung machine to move critically ill patients easily and safely to different areas of the hospital for medical tests or from outlying hospitals to the medical center for specialized treatment. Recently approved for use in the U.S. by the FDA, the device has been used in Europe since 2008 with excellent results.

21 Jul 2010

Transplant News and Research

Clinical Pharmacokinetics Research Laboratory deploys AB SCIEX mass spectrometry technology

Researchers establish new criteria for liver transplantation

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

FDA approves addition of 10 sites to WorldHeart's Levacor VAD BTT clinical study

SBHCS deploys MedeAnalytics platform to automate patient access process of health system

New partnership brings latest stem cell discoveries from laboratory to patient

Waters to present MassTrak solutions at American Association of Clinical Chemistry annual meeting

Abbot's innovative solutions to be highlighted at AACC

UCLA Health System launches hand transplantation program

CPC partners with CU School of Medicine on stem cell research

New guidelines for care of heart transplant recipients from ISHLT

Methodist surgical team completes first phase training to implant new total artificial heart

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Towards a cure: HIV reservoirs and strategies to control them

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Genzyme second-quarter revenue decreases to $1.08 billion

First hospital in U.S. to use portable heart/lung machine

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News